The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

BACKGROUND: CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) represents a promising treatment modality for an increasing number of B-cell malignancies. However, prolonged cytopenias and infections substantially contribute to the toxicity burden of CAR-T. The recently developed CAR-HEMA...

Descripción completa

Detalles Bibliográficos
Autores principales: Rejeski, Kai, Perez, Ariel, Iacoboni, Gloria, Penack, Olaf, Bücklein, Veit, Jentzsch, Liv, Mougiakakos, Dimitrios, Johnson, Grace, Arciola, Brian, Carpio, Cecilia, Blumenberg, Viktoria, Hoster, Eva, Bullinger, Lars, Locke, Frederick L, von Bergwelt-Baildon, Michael, Mackensen, Andreas, Bethge, Wolfgang, Barba, Pere, Jain, Michael D, Subklewe, Marion
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114843/
https://www.ncbi.nlm.nih.gov/pubmed/35580927
http://dx.doi.org/10.1136/jitc-2021-004475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114843/
https://www.ncbi.nlm.nih.gov/pubmed/35580927
http://dx.doi.org/10.1136/jitc-2021-004475

Ejemplares similares